These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 27117440)
1. 9-Month Efficacy and Safety Study of Testosterone Solution 2% for Sex Drive and Energy in Hypogonadal Men. Brock G; Heiselman D; Knorr J; Ni X; Kinchen K J Urol; 2016 Nov; 196(5):1509-1515. PubMed ID: 27117440 [TBL] [Abstract][Full Text] [Related]
2. Effect of Testosterone Solution 2% on Testosterone Concentration, Sex Drive and Energy in Hypogonadal Men: Results of a Placebo Controlled Study. Brock G; Heiselman D; Maggi M; Kim SW; Rodríguez Vallejo JM; Behre HM; McGettigan J; Dowsett SA; Hayes RP; Knorr J; Ni X; Kinchen K J Urol; 2016 Mar; 195(3):699-705. PubMed ID: 26498057 [TBL] [Abstract][Full Text] [Related]
3. Demographic and Clinical Correlates of Patient-Reported Improvement in Sex Drive, Erectile Function, and Energy With Testosterone Solution 2. Wu F; Zitzmann M; Heiselman D; Donatucci C; Knorr J; Patel AB; Kinchen K J Sex Med; 2016 Aug; 13(8):1212-9. PubMed ID: 27329542 [TBL] [Abstract][Full Text] [Related]
4. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357 [TBL] [Abstract][Full Text] [Related]
5. Short term testosterone replacement therapy improves libido and body composition. Andrade ES; Clapauch R; Buksman S Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):996-1004. PubMed ID: 20126853 [TBL] [Abstract][Full Text] [Related]
6. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A; Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400 [TBL] [Abstract][Full Text] [Related]
8. Psychometric testing of two new patient-reported outcome instruments for the evaluation of treatment for hypogonadism. Hayes RP; Ni X; Heiselman DE; Kinchen K Int J Clin Pract; 2016 Jul; 70(7):587-95. PubMed ID: 27291501 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open-label studies. Belkoff L; Brock G; Carrara D; Neijber A; Ando M; Mitchel J Andrologia; 2018 Feb; 50(1):. PubMed ID: 28295450 [TBL] [Abstract][Full Text] [Related]
10. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism. Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499 [TBL] [Abstract][Full Text] [Related]
11. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men. Behre HM; Heinemann L; Morales A; Pexman-Fieth C Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057 [TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). Shores MM; Kivlahan DR; Sadak TI; Li EJ; Matsumoto AM J Clin Psychiatry; 2009 Jul; 70(7):1009-16. PubMed ID: 19653976 [TBL] [Abstract][Full Text] [Related]
14. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. Kaminetsky JC; Moclair B; Hemani M; Sand M J Sex Med; 2011 Apr; 8(4):1186-96. PubMed ID: 21269402 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Davis S; Papalia MA; Norman RJ; O'Neill S; Redelman M; Williamson M; Stuckey BG; Wlodarczyk J; Gard'ner K; Humberstone A Ann Intern Med; 2008 Apr; 148(8):569-77. PubMed ID: 18413618 [TBL] [Abstract][Full Text] [Related]
16. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N; J Clin Endocrinol Metab; 2000 Aug; 85(8):2839-53. PubMed ID: 10946892 [TBL] [Abstract][Full Text] [Related]
17. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome. Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974 [TBL] [Abstract][Full Text] [Related]
18. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial. Ng Tang Fui M; Hoermann R; Prendergast LA; Zajac JD; Grossmann M Int J Obes (Lond); 2017 Mar; 41(3):420-426. PubMed ID: 28028318 [TBL] [Abstract][Full Text] [Related]
19. Testosterone for low libido in postmenopausal women not taking estrogen. Davis SR; Moreau M; Kroll R; Bouchard C; Panay N; Gass M; Braunstein GD; Hirschberg AL; Rodenberg C; Pack S; Koch H; Moufarege A; Studd J; N Engl J Med; 2008 Nov; 359(19):2005-17. PubMed ID: 18987368 [TBL] [Abstract][Full Text] [Related]